nAMD Clinical Trials
3 recruiting trials for nAMD. Eligibility criteria explained in plain English.
3
Total Trials
3
Recruiting Now
1
Phase 3 Trials
2
Sponsors
Recruiting Trials
RECRUITINGPhase 2 / Phase 3NCT04704921
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in...
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD)....
Sponsor: AbbVieEnrolling: 63020 locations
RECRUITINGPhase 3NCT05407636
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD...
Sponsor: AbbVieEnrolling: 66020 locations
RECRUITINGPhase 1 / Phase 2NCT06672536
Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
Sponsor: Sinocelltech Ltd.Enrolling: 821 location